SCHEDULE: Millennium Entities Report 5.5% Stake in Quoin Pharmaceuticals

Several entities affiliated with Millennium Management have reported beneficial ownership of 5.5% of Quoin Pharmaceuticals Ltd.'s ordinary shares.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 3,850,385 ordinary shares of Quoin Pharmaceuticals Ltd.
• This represents 5.5% of the class of securities.
• The filing date is May 26, 2026, with the report filed on or about June 1, 2026.
• The reporting persons are investment advisors and related entities.
• The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of ownership and does not contain operational or financial performance data for the issuer.

Positives

• The filing clearly discloses a significant ownership stake, providing transparency to the market.
• The joint filing agreement confirms coordinated reporting among related entities.

Negatives

• The filing does not provide any financial performance data or operational updates for Quoin Pharmaceuticals Ltd., making it difficult to assess the underlying value of the investment.
• The nature of the beneficial ownership is complex, with shares held by entities subject to control by Millennium Management LLC and Mr. Englander, which may obscure direct individual beneficial ownership.

Risks

• The filing does not detail specific risks related to Quoin Pharmaceuticals Ltd. or the investment itself, beyond the general risks associated with stock ownership.
• The complex ownership structure could lead to future governance or control disputes if not clearly managed.

Future Outlook

No forward-looking statements or guidance regarding Quoin Pharmaceuticals Ltd. are provided in this filing.

Management Comments

• The filing states: 'The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.'
• The filing also notes: 'Each American Depositary Share represents thirty-five Ordinary Shares. No CUSIP number has been assigned to the issuer's Ordinary Shares.'

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates a substantial investment by entities associated with Millennium Management in Quoin Pharmaceuticals Ltd., a biotechnology or pharmaceutical company, suggesting a strategic interest in the sector.

Stakeholder Impact

• Shareholders of Quoin Pharmaceuticals Ltd. are informed of a significant institutional investor's stake, which could influence market perception and trading activity.
• The reporting entities (Millennium Management, etc.) are demonstrating their investment strategy and market presence.

Next Steps

• Continued monitoring of Quoin Pharmaceuticals Ltd. for further disclosures or operational updates.
• Potential for further filings if ownership levels change significantly.

Key Dates

Keywords

Schedule 13G, Quoin Pharmaceuticals, Millennium Management, Integrated Core Strategies, Beneficial Ownership, Ordinary Shares, SEC Filing, Investment Management